this experience includes ( 1 ) 28-week double-blind study of hydralazine vs placebo in 19 patients with chf , ( 2 ) 52-week double-blind crossover study of trimazosin ( alpha 1 blockade ) vs placebo in 27 patients with chf of varying severity , and ( 3 ) open study of amrinone ( positive inotropic agent ) in 12 patients with chf .
C0020223
hydralazine
C0018802
chf